amd

Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD).

Lampalizumab (RG 7417) is a humanized monoclonal antibody targeting Complement Factor D in the complement pathway, used in age-related macular degeneration (AMD) and cardiovascular disease research.

Tarcocimab (OG1953), a humanized IgG1-type anti-VEGFA monoclonal antibody, is utilized in research targeting conditions such as retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

Galegenimab (FHTR 2163; RG 6147; RO 7171009), an antibody fragment targeting High-temperature requirement A1 (HTRA1), is utilized in research on age-related macular degeneration (AMD) [1].